Avid Bioservices Inc (CDMO)

[biopharm]

Laura Benjamin and team with PS Targeting based Biomarkers on the way ...

_____

SITC 2019

Nov 6-10, 2019

.....
.....
....

P108

Working Towards Precision Medicine of the Tumor Microenvironment

Kristen Strand-Tibbitts, PhD;

Kyung Kim, PhD;

Jeeyun Kim;

Seung-Tae Kim;

Jung-Yong Hong;

Laura Benjamin;

Kristen Strand-Tibbitts, PhD;


Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics; Biomarkers; Gene expression; Solid tumors; Targeted therapy; Tumor microenvironment


All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.

Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).

https://sitc.sitcancer.org/2019/abstracts/titles/index.php?filter=Laura+Benjamin

One never knows what else is on the way..

Nov. 5, 2019 Embargo Lifted and Full Regular and Late-Breaking Abstracts Made Public at 8 a.m. EST
Regular Abstract Supplement Published in JITC

https://www.sitcancer.org/2019/abstracts/abstract-information

Jianda Yuan (Merck) to Raphael Clymes (Xencor) to Oncologie to Thomas W Dubensky (ex Immune Design PS Targeting patents w/Merck) may be Tempest to tell how PS Targeting required especially with BGB324 BerGenBio ties to Rolf Brekken / Longen Zhou and many more ...Many well aware especially some new NEW IIS : )


Poster Symposium
Time:
Location:
Co-Chairs:
5:30 – 7:30 p.m.
Potomac Ballroom CD
Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Institute
Roberta Zappasodi, PhD - Memorial Sloan Kettering Institute

...
...

Session 204: Immune Checkpoints: Newer Targets and Update on Combinations
Time:
Location:
Co-Chairs: 2:00 – 4:20 p.m.
Potomac Ballroom
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and
Research Institute
....
....

5:10 p.m. (O26) A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis
Matthew G. Krebs, MD, PhD –The University of Manchester
...
...

https://www.sitcancer.org/2019/program/annual-meeting-schedule-2019-old